Table 2 Patient characteristics of survival time.

From: Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan

 

Survival < 3 year

Survival ≥ 3 year

p-value

n = 155

n = 106

 

Age

75.0 [20‒92]

71.0 [40‒80]

< 0.001

Male

125 (80.6)

68 (64.2)

0.16

BMI, kg/m2

21.9 [8.2‒31.5]

24.1 [11.1‒32.6]

< 0.001

Smoking status

   

Former/Current

120 (77.4)

71 (67.0)

0.04

Disease

   

IPF

75 (48.4)

51 (48.1)

0.96

IIPs

36 (23.2)

24 (22.6)

 

CTD-ILD

28 (18.1)

21 (19.8)

 

PPFE

9 (5.8)

7 (6.6)

 

HP

5 (3.2)

3 (2.8)

 

CT pattern

   

UIP

106 (68.4)

68 (64.2)

0.88

fNSIP

34 (21.9)

26 (24.5)

 

PPFE

8 (5.2)

7 (6.6)

 

Unclassifiable

7 (4.5)

5 (4.7)

 

Past acute exacerbation

29 (18.7)

14 (13.2)

0.31

Medication

   

Glucocorticoid

57 (36.8)

26 (24.5)

0.04

Immunosuppressant

24 (15.5)

15 (14.2)

0.86

Severity Ⅲ, Ⅳ

77 (49.7)

36 (36.8)

0.01

mMRC 2‒4

78 (50.8)

36 (36.8)

0.001

Resting SpO2 < 95% a

69 (44.5)

19 (18.0)

< 0.001

LTOT

40 (25.8)

11 (10.4)

0.002

Blood test

   

ALB, g/dL

3.7 [2.4‒5.0]

4.0 [3.1‒4.6]

< 0.001

LDH, U/L

234.0 [139.0‒818.0]

218.0 [142.0‒401.0]

0.004

CRP, mg/dL

0.37 [0.01‒8.02]

0.19 [0.00‒25.73]

< 0.001

KL-6, U/mL

926.0 [261.0‒5570.0]

997.0 [160.0‒4749.0]

0.97

NLR

2.6 [0.72‒37.60]

2.9 [0.3‒25.4]

0.08

PNI

48.7 [33.2‒60.5]

48.0 [27.5‒71.0]

0.21

Pulmonary function test

   

%FVC

60.9 [23.6‒112.7]

75.7 [37.3‒131.2]

< 0.001

%DLco

52.7 [14.4‒112.6]

58.6 [30.2‒108.0]

0.15

Days from diagnosis to initiation of nintedanib

588.0 [-302‒5596]

220.0 [-1166‒5660]

0.07

  1. Data are expressed as medians [ranges], or N (%). %DLco, % diffusing capacity of the lungs for carbon monoxide; %FVC, % forced vital capacity; ALB, albumin; BMI, body mass index; CRP, C-reactive protein; CTD-ILD, connective tissue disease-associated interstitial lung disease; fNSIP, fibrotic non-specific interstitial pneumonia; HP, hypersensitivity pneumonitis; IIPs, idiopathic interstitial pneumonias; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; LTOT, long-term oxygen therapy; mMRC, modified Medical Research Council; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; PPFE, pleuroparenchymal fibroelastosis; SpO₂, saturation of arterial oxygen; UIP, usual interstitial pneumonia. a Those who could not measure their resting SpO2 with room air due to oxygen administration were included in resting SpO2 < 95%.
Back to article page